Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;182(15):3539-3558.
doi: 10.1111/bph.70026. Epub 2025 Apr 1.

Annexin A1/FPR2 pathway modulates leukocyte function during Escherichia coli-induced pneumonia to promote resolution of inflammation and restores lung function

Edvaldo S Lara  1   2 , Antônio Felipe S Carvalho  1   2 , Camila Cardoso  1 , Isabella Zaidan  1 , Laís C Grossi  1 , Fernanda S Carneiro  1   2 , Erick Bryan S Lima  1   2 , Adelson Heric A Monteiro  1 , Rodrigo S Caixeta  1 , Isabella L Augusto  1 , Ana Clara M Montuori-Andrade  1 , Lívia Cristina R Teixeira  1 , Celso M Queiroz-Junior  3 , Remo C Russo  4 , Mauro Perretti  5 , Vivian V Costa  3 , Mauro M Teixeira  3 , Luciana P Tavares  6 , Lirlândia P Sousa  1   2
Affiliations

Annexin A1/FPR2 pathway modulates leukocyte function during Escherichia coli-induced pneumonia to promote resolution of inflammation and restores lung function

Edvaldo S Lara et al. Br J Pharmacol. 2025 Aug.

Abstract

Background and purpose: Gram-negative bacteria are the main causes of pneumonia in the nosocomial environment. Inflammation triggered during pneumonia is necessary for bacterial clearance but must be spatially and temporally regulated to prevent further tissue damage and bacterial dissemination. Emerging data shows that annexin A1 (ANXA1) signalling through its receptor FPR2 promotes host resistance and resilience in preclinical models of infectious disease.

Experimental approach: Using a mouse model of Escherichia coli-induced pneumonia, the role of ANXA1/FPR2 on key steps of inflammation resolution was evaluated.

Key results: Anxa1 and Fpr2/3 knockout mice, intranasally infected with E. coli, exhibited exacerbated neutrophilic inflammation, higher bacterial dissemination, decreased neutrophil apoptosis/efferocytosis counts in the airways and higher levels of inflammatory cytokines/chemokines coupled to marked lung damage and dysfunction, as compared to WT mice. Treatment of WT-infected mice with the ANXA1 peptidomimetic, annexin I-(2-26), decreased inflammation, increased apoptosis/efferocytosis of neutrophils and improved bacterial clearance in the airways and lungs, resulting in an improvement of lung function. The pan-caspase inhibitor Z-VAD-FMK prevented annexin I-(2-26)-induced resolution of the neutrophilic inflammation, underlining neutrophil apoptosis as the main mechanism for annexin I-(2-26) promotion of resolution of E. coli pneumonia. In addition, annexin I-(2-26) treatment increased the numbers of airway macrophages of infected mice and promoted macrophage phagocytosis of E. coli in vitro.

Conclusions and implications: In summary, these findings highlight the role for ANXA1/FPR2 pathway as a nonredundant resolution mechanism for E. coli-induced pneumonia and demonstrate that annexin I-(2-26) as a potential host-directed therapeutic approach to treat infectious lung diseases.

Keywords: FPR2; annexin A1; inflammation; pneumonia; resolution of infection.

PubMed Disclaimer

References

REFERENCES

    1. Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A. A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Davies, J. A., Annett, S., Boison, D., Burns, K. E., Dessauer, C., Gertsch, J., Helsby, N. A., Izzo, A. A., Ostrom, R., Papapetropoulos, A., … Wong, S. S. (2023). The concise guide to PHARMACOLOGY 2023/24: Enzymes. British Journal of Pharmacology, 180(Suppl 2), S289–S373. https://doi.org/10.1111/bph.16181
    1. Alexander, S. P. H., Kelly, E., Mathie, A. A., Peters, J. A., Veale, E. L., Armstrong, J. F., Buneman, O. P., Faccenda, E., Harding, S. D., Spedding, M., Cidlowski, J. A., Fabbro, D., Davenport, A. P., Striessnig, J., Davies, J. A., Ahlers‐Dannen, K. E., Alqinyah, M., Arumugam, T. V., Bodle, C., … Zolghadri, Y. (2023). The concise guide to PHARMACOLOGY 2023/24: Introduction and other protein targets. British Journal of Pharmacology, 180(Suppl 2), S1–S22. https://doi.org/10.1111/bph.16176
    1. Alexander, S. P. H., Roberts, R. E., Broughton, B. R. S., Sobey, C. G., George, C. H., Stanford, S. C., Cirino, G., Docherty, J. R., Giembycz, M. A., Hoyer, D., Insel, P. A., Izzo, A. A., Ji, Y., MacEwan, D. J., Mangum, J., Wonnacott, S., & Ahluwalia, A. (2018). Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology. British Journal of Pharmacology, 175(3), 407–411. https://doi.org/10.1111/bph.14112
    1. Allocati, N., Masulli, M., Alexeyev, M. F., & Di Ilio, C. (2013). Escherichia coli in Europe: An overview. International Journal of Environmental Research and Public Health, 10(12), 6235–6254. https://doi.org/10.3390/ijerph10126235
    1. Añón, J. M., & Villar, J. (2021). Ten reasons why corticosteroid therapy reduces mortality in severe COVID‐19. Intensive Care Medicine, 47(3), 355–356. https://doi.org/10.1007/s00134-020-06330-w

MeSH terms